Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 11
2004 5
2005 10
2006 17
2007 10
2008 18
2009 18
2010 19
2011 20
2012 23
2013 27
2014 30
2015 32
2016 49
2017 44
2018 54
2019 42
2020 51
2021 66
2022 49
2023 61
2024 60
2025 64
2026 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

700 results

Results by year

Filters applied: . Clear all
Page 1
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?
Selimoglu-Buet D, Chevret S, Santini V, Thépot S, Morabito M, Adès L, Laplane L, Giagounidis A, Droin N, Lübbert M, Sapena R, Nimubona S, Torregrosa-Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Paul F, Patriarca A, Stamatoullas A, Götze K, Chermat F, Platzbecker U, Fenaux P, Solary E, Itzykson R. Selimoglu-Buet D, et al. Among authors: nimubona s. Leukemia. 2026 Mar 9. doi: 10.1038/s41375-026-02901-w. Online ahead of print. Leukemia. 2026. PMID: 41803403
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
Canelo-Vilaseca M, Sabbah M, Cristinelli C, Bommier C, Sesques P, Roussel M, Bories P, Allain V, Ouedrani A, De Bernardis I, Vely A, Stephan P, Vercellino L, Venet F, Pescarmona R, Houot R, Vergez F, de Jorna R, Madelaine I, Parquet N, Brignier AC, Larghero J, Mebarki M, Di Blasi R, Caillat-Zucman S, Thieblemont C. Canelo-Vilaseca M, et al. Among authors: houot r. Bone Marrow Transplant. 2026 Mar 2. doi: 10.1038/s41409-026-02809-0. Online ahead of print. Bone Marrow Transplant. 2026. PMID: 41772123 No abstract available.
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).
Talbot A, Delcour B, Gillot L, Arnulf B, Avet Loiseau H, Boccaccio C, Frenzel L, Karlin L, Kraeuter K, Macro M, Mohty M, Perrot A, Touzeau C, Sonntag C, Hulin C, Moreau P, Decaux O. Talbot A, et al. Among authors: decaux o. JMIR Form Res. 2026 Feb 25;10:e81225. doi: 10.2196/81225. JMIR Form Res. 2026. PMID: 41740161 Free PMC article.
[Generations at work: From gaps to shared strength].
Revol O, Houot R, Gyan E. Revol O, et al. Among authors: houot r. Bull Cancer. 2026 Mar;113(3):288-289. doi: 10.1016/j.bulcan.2025.11.013. Epub 2026 Feb 11. Bull Cancer. 2026. PMID: 41679980 French. No abstract available.
Infectious events in fit patients with relapsed or refractory acute myeloid leukemia treated with azacitidine-venetoclax or intensive chemotherapy.
Bobo M, Lefevre L, Mallet-Guy P, Chacon A, Eloit M, Chevallier P, Peterlin P, Mear JB, Marchand T, Gallego-Hernanz MP, Mokeddem C, Gyan E, Tanguy-Schmidt A, Vallet N; FHU GOAL. Bobo M, et al. Among authors: mear jb, marchand t. Int J Infect Dis. 2026 Mar;164:108412. doi: 10.1016/j.ijid.2026.108412. Epub 2026 Jan 19. Int J Infect Dis. 2026. PMID: 41565057 Free article.
Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.
Charton E, Anota A, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Dulery R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Llamas Gutierrez F, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F, Houot R. Charton E, et al. Among authors: houot r. Blood Adv. 2026 Mar 10;10(5):1773-1782. doi: 10.1182/bloodadvances.2025018057. Blood Adv. 2026. PMID: 41512176 Free PMC article. Clinical Trial.
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
Canelo-Vilaseca M, Sabbah M, Cristinelli C, Bommier C, Sesques P, Roussel M, Bories P, Allain V, Ouedrani A, De Bernardis I, Vely A, Stephan P, Vercellino L, Venet F, Pescarmona R, Houot R, Vergez F, de Jorna R, Madelaine I, Parquet N, Brignier AC, Larghero J, Mebarki M, Di Blasi R, Caillat-Zucman S, Thieblemont C. Canelo-Vilaseca M, et al. Among authors: houot r. Bone Marrow Transplant. 2026 Jan 8. doi: 10.1038/s41409-025-02754-4. Online ahead of print. Bone Marrow Transplant. 2026. PMID: 41507382 No abstract available.
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.
Quinquenel A, Letestu R, Le Garff-Tavernier M, Morisset S, Subtil F, Aurran T, Laribi K, Cymbalista F, Lévy V, Simon L, Roos-Weil D, Leblond V, Dilhuydy MS, Tomowiak C, Dartigeas C, Guièze R, Tournilhac O, Ferrant E, de Guibert S, Feugier P, Merabet F, Leprêtre S, Carassou P, Gay J, Hivert B, Fornecker LM, Dupuis J, Molina L, Villemagne B, Cartron G, Drenou B, Mahé B, Benbrahim O, Cahu X, Portois C, Ysebaert L, Nguyen-Khac F, Dahmani A, Quiney C, Rouillé V, Delmer A, Michallet AS. Quinquenel A, et al. Among authors: de guibert s. EClinicalMedicine. 2025 Dec 17;91:103707. doi: 10.1016/j.eclinm.2025.103707. eCollection 2026 Jan. EClinicalMedicine. 2025. PMID: 41502925 Free PMC article.
Hematologic Landscape of Adult Patients With Diamond-Blackfan Anemia Syndrome.
Lecornec N, de Fontbrune FS, Forcade E, Garçon L, Terriou L, Cougoul P, Delavigne K, Marie I, Brindel I, Deconinck É, Daguindau É, Amé S, Ledoux MP, Sanhes L, Nimubona S, Leverger G, de Montalembert M, de Latour RP, Dalle JH, Fenaux P, Costa LD, Leblanc T. Lecornec N, et al. Among authors: nimubona s. Am J Hematol. 2026 Jan 7. doi: 10.1002/ajh.70197. Online ahead of print. Am J Hematol. 2026. PMID: 41498485
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis.
Galtier J, Sesques P, Dupont V, Bachy E, Di Blasi R, Thieblemont C, Brisou G, Gastinne T, Cartron G, Gros FX, Morschhauser F, André A, Bay JO, Joris M, Tanguy-Schmidt A, Demailly A, Le Gouill S, Houot R, Bouabdallah K, Camus V. Galtier J, et al. Among authors: houot r. Hemasphere. 2025 Dec 8;9(12):e70263. doi: 10.1002/hem3.70263. eCollection 2025 Dec. Hemasphere. 2025. PMID: 41368077 Free PMC article. No abstract available.
Large B-cell lymphoma: The LYSA pragmatic guidelines.
Sesques P, Manson G, Dubois S, Gros FX, Brisou G, Sarkozy C, Bernard S, Bourbon E, Fornecker LM, Durot E, Martin L, Chassagne-Clément C, Llamas Gutierrez F, Syrykh C, Delfau-Larue MH, Kanoun S, Vercellino L, Bodet-Milin C, Bahri H, Zhang Yin J, Dony A, Lebras L, Ochmann M, Baron M, Monjanel H, Le Calloch R, Claves F, Kirova Y, Gisselbrecht C, Guidez S, Bossard JB, Di Blasi R, Delette C, Fouillet L, Rhomdani M, Belhadj M, Crochet G, Amorim S, Safa F, Drieu La Rochelle L, Abraham J, Thieblemont C, Jardin F, Noel R, Bailly S, Renaud L, Guillermin Y, Delapierre B, Choquet S, Roulin L, Lamure S, Galicier L, Al Tabaa Y, Soussain C, Guièze R, Houot R, Tessoulin B. Sesques P, et al. Among authors: houot r, manson g. Eur J Cancer. 2026 Jan;232:116070. doi: 10.1016/j.ejca.2025.116070. Epub 2025 Dec 3. Eur J Cancer. 2026. PMID: 41352004 Free article.
Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study.
Maguet R, Eloit M, Chinot O, Soubeyran P, Soussain C, Houot R, Ahle G, Delwail V, Clavert A, Oberic L, Ursu R, Sellenart H, Abraham J, Herault O, Houillier C, Gyan E. Maguet R, et al. Among authors: houot r. Ann Hematol. 2025 Dec;104(12):6385-6390. doi: 10.1007/s00277-025-06654-x. Epub 2025 Nov 27. Ann Hematol. 2025. PMID: 41307678 Free PMC article.
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3.
van Meerten T, Kersten MJ, Iacoboni G, Hess GR, Mutsaers PGNJ, Martin Garcia-Sancho AM, Goy A, Gine E, Hill BT, Weng WK, Reagan PM, Patel K, Galal A, Herbaux C, Sanderson R, Forcade E, Topp MS, Houot R, Zheng D, Zhang W, Kanska J, Shen RR, Damico Khalid R, Kloos I, Dreyling M, Wang ML. van Meerten T, et al. Among authors: houot r. Blood. 2025 Oct 29:blood.2025029734. doi: 10.1182/blood.2025029734. Online ahead of print. Blood. 2025. PMID: 41160777
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Moreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A. Moreau P, et al. Among authors: escoffre barbe m. Blood Cancer J. 2025 Oct 24;15(1):177. doi: 10.1038/s41408-025-01387-6. Blood Cancer J. 2025. PMID: 41136366 Free PMC article. Review.
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.
Boissel N, Chevret S, Huguet F, Leguay T, Hunault M, Graux C, Chalandon Y, Delabesse E, Hicheri Y, Chevallier P, Balsat M, Pastoret C, Escoffre-Barbe M, Pasquier F, Joris M, Thiebaut A, Huynh A, Dhédin N, Lemasle E, Bonmati C, Maury S, Guillerm G, Berceanu A, Manz M, Cluzeau T, Turlure P, Rousselot P, de Prijck B, Grardel N, Béné MC, Lafage-Pochitaloff M, Cuccuini W, Ifrah N, Lhéritier V, Asnafi V, Clappier E, Dombret H. Boissel N, et al. Among authors: escoffre barbe m. Blood. 2026 Feb 19;147(8):821-833. doi: 10.1182/blood.2025029611. Blood. 2026. PMID: 41135009
Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.
Erbella F, Bachy E, Cartron G, Gat E, Manson G, Morschhauser F, Gros FX, Roulin L, Tessoulin B, Bories P, Tournilhac O, Ricard L, Guidez S, Choquet S, Casasnovas RO, Brisou G, Campidelli A, Castilla-Llorente C, Jardin F, Gyan E, Guffroy B, Abraham J, Decroocq J, Chauchet A, Joris M, Claves F, Carras S, Guillerm G, Loschi M, Hermine O, Taguy-Schimidt A, Le Gouill S, Houot R, Di Blasi R. Erbella F, et al. Among authors: houot r, manson g. Blood Adv. 2026 Jan 27;10(2):392-401. doi: 10.1182/bloodadvances.2025016727. Blood Adv. 2026. PMID: 41124667 Free PMC article.
Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d'Enregistrement et Suivi des patients traités par CAR-T cells) registry.
Bouvier A, Durand A, Dupont V, Gower N, Lorente CC, Campidelli A, Dulery R, Gangneux JP, Joris M, Eloit M, Latiere C, di Blasi R, Denis B, Gabellier L, Morschhauser F, Casasnovas O, Houot R, Angebault C, Bachy E, Le Bras F, Gastinne T, Tudesq JJ, Lemonnier F, Melica G. Bouvier A, et al. Among authors: houot r. Clin Microbiol Infect. 2026 Feb;32(2):277-284. doi: 10.1016/j.cmi.2025.10.005. Epub 2025 Oct 16. Clin Microbiol Infect. 2026. PMID: 41109429 Free article.
Hypereosinophilia after CAR T-cell therapy.
Poirier B, Houot R, Vic S, Roussel M, Henry C, Pastoret C, Messéant O. Poirier B, et al. Among authors: houot r, messeant o. Leuk Lymphoma. 2025 Dec;66(14):2786-2789. doi: 10.1080/10428194.2025.2565466. Epub 2025 Oct 16. Leuk Lymphoma. 2025. PMID: 41099313 No abstract available.
Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.
Ferrant J, Le Gallou S, Padonou F, Dubec-Fleury C, Leonard S, Papa I, Brottier C, Pangault C, Barthel A, Launay V, Manson G, Hoareau B, Deleurme L, Monvoisin C, Albaud B, Shipp MA, Van Acker N, Laurent C, Llamas Gutierrez F, Michaud HA, Bonnefoy N, Pécot T, Tarte K, Roussel M. Ferrant J, et al. Among authors: manson g. Blood Adv. 2026 Feb 24;10(4):1217-1232. doi: 10.1182/bloodadvances.2024015689. Blood Adv. 2026. PMID: 41061154 Free PMC article.
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.
Manier S, Lambert J, Hulin C, Macro M, Laribi K, Araujo C, Pica GM, Touzeau C, Godmer P, Slama B, Karlin L, Orsini Piocelle F, Dib M, Sanhes L, Morel P, El Yamani A, Tiab M, Tabrizi R, Richez V, Garderet L, Royer B, Bareau B, Mariette C, Fleck E, Robu D, Calmettes C, Rigaudeau S, Demarquette H, Frenzel L, Decaux O, Mohty M, Arnulf B, Bigot N, Perrot A, Corre J, Mary JY, Avet-Loiseau H, Moreau P, Leleu X, Facon T. Manier S, et al. Among authors: decaux o. Lancet Oncol. 2025 Oct;26(10):1323-1333. doi: 10.1016/S1470-2045(25)00280-3. Lancet Oncol. 2025. PMID: 41038184 Free article. Clinical Trial.
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
Aymard M, Cheminant M, Houot R, Cuozzo A, Gat E, Thieblemont C, Ricard L, Roulin L, Bouabdallah K, Safar V, Guidez S, Fayard A, Brisou G, Ysebaert L, Hermine O, Tessoulin B, Herbaux C, Le Gouill S, Sarkozy C. Aymard M, et al. Among authors: houot r. Blood Adv. 2026 Jan 13;10(1):75-82. doi: 10.1182/bloodadvances.2025017234. Blood Adv. 2026. PMID: 41026973 Free PMC article.
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study.
Cazaubiel T, Decaux O, Royer B, Caillot D, Bobin A, Belhadj-Merzoug K, Macro M, Vincent L, Perrot A, Mohty M, Karlin L, Jacquet C, Frenzel L, Chalopin T, Sonntag C, Fontan J, Rigaudeau S, Touzeau C, Demarquette H, Chaib A, Santana C, Darre S, Bareau B, Garlantézec R, Hulin C. Cazaubiel T, et al. Among authors: decaux o. Clin Hematol Int. 2025 Sep 18;7(3):60-68. doi: 10.46989/001c.143641. eCollection 2025. Clin Hematol Int. 2025. PMID: 40978559 Free PMC article.
Real-World Utilization of Carfilzomib (Once or Twice Weekly) Initiated in Patients After a First Relapse Between 2017 and 2022 in France: An Analysis From a Large-Scale Epidemiology of Multiple MYeloma (EmmY) Cohort.
Hulin C, Belhadj Merzoug K, Royer B, Caillot D, Bobin A, Macro M, Karlin L, Mohty M, Frenzel L, Perrot A, Vincent L, Dib M, Piocell FO, Benramdane R, Calmettes C, Chalopin T, Garlantézec R, Désaméricq G, Mechiche H, Decaux O. Hulin C, et al. Among authors: decaux o. Clin Lymphoma Myeloma Leuk. 2026 Jan;26(1):e1-e11.e4. doi: 10.1016/j.clml.2025.08.002. Epub 2025 Aug 7. Clin Lymphoma Myeloma Leuk. 2026. PMID: 40967989 Free article.
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.
Cayla S, Karlin L, Lambert J, Lazareth A, Talbot A, Mohty M, Malard F, Petillon MO, Manier S, Yakoub-Agha I, Caillot D, Lafon I, Leleu X, Moya N, Royer B, Schiano De Colella JM, Brisou G, Touzeau C, Perrot A, Bories P, Vincent L, Guedon H, Decaux O, Ferment B, Houot R, Le Gouill S, Bigot N, Facon T, Corre J, Avet-Loiseau H, Moreau P, Arnulf B. Cayla S, et al. Among authors: houot r, decaux o. Blood Adv. 2026 Feb 24;10(4):1324-1333. doi: 10.1182/bloodadvances.2025017597. Blood Adv. 2026. PMID: 40966637 Free PMC article.
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.
Jullien M, Brissot E, Daguindau E, Loschi M, Bazarbachi A, Labussiere-Wallet H, Huynh A, Schmidt-Tanguy A, Charbonnier A, Turlure P, Beckerich F, Devillier R, Bay JO, Srour M, Ceballos P, Alani M, Souchet L, Marchand T, Rubio MT, Forcade E, Cornillon J, Chantepie S, Bulabois CE, Villate A, Garnier A, Peterlin P, Le Bourgeois A, Guillaume T, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Jullien M, et al. Among authors: marchand t. Bone Marrow Transplant. 2025 Dec;60(12):1592-1600. doi: 10.1038/s41409-025-02709-9. Epub 2025 Sep 15. Bone Marrow Transplant. 2025. PMID: 40954245
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM study.
Orvain C, Tavitian S, Mediavilla C, Boyer F, Santagostino A, Venton G, Madene S, Marchand T, Turlure P, Lara D, Le Clech L, Le Du K, Robin JB, Willems L, Blouet A, Systchenko T, Wemeau M, Pasquer H, Mercier M, Nicol C, Legros L, Machet A, Nicolini FE, Roy L, Salvado C, Denis G, Lestang E, Laribi K, Luque Paz D, Kiladjian JJ, Lippert E, Benajiba L, Ianotto JC. Orvain C, et al. Among authors: marchand t. Hemasphere. 2025 Sep 4;9(9):e70202. doi: 10.1002/hem3.70202. eCollection 2025 Sep. Hemasphere. 2025. PMID: 40918085 Free PMC article.
Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.
Chalopin T, Hulin C, Royer B, Bastie JN, Bobin A, Merzoug KB, Macro M, Karlin L, Jacquet C, Mohty M, Frenzel L, Sonntag C, Fontan J, Rigaudeau S, Roussel M, Sanhes L, Chaoui D, Vincent L, Orfeuvre H, Bouketouche M, Garlantezec R, Decaux O, Perrot A. Chalopin T, et al. Among authors: decaux o. Haematologica. 2026 Feb 1;111(2):728-732. doi: 10.3324/haematol.2025.287954. Epub 2025 Aug 28. Haematologica. 2026. PMID: 40874328 Free PMC article. No abstract available.
Haematopoietic stem cell number is not solely defined by niche availability.
Takeishi S, Marchand T, Koba WR, Borger DK, Xu C, Guha C, Bergman A, Frenette PS, Gritsman K, Steidl U. Takeishi S, et al. Among authors: marchand t. Nature. 2025 Oct;646(8085):687-696. doi: 10.1038/s41586-025-09462-5. Epub 2025 Aug 27. Nature. 2025. PMID: 40866696 Free PMC article.
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.
Chalopin T, Decaux O, Hulin C, Perrot A, Macro M, Royer B, Bastie JN, Bobin A, Jacquet C, Mohty M, Frenzel L, Sonntag C, Roussel M, Sanhes L, Chaoui D, Dib M, Slama B, Richez V, Montes L, Dervite I, Laribi K, Re D, Garlantezec R, Merzoug KB, Vincent L. Chalopin T, et al. Among authors: decaux o. Clin Lymphoma Myeloma Leuk. 2025 Oct;25(10):759-762. doi: 10.1016/j.clml.2025.07.009. Epub 2025 Jul 24. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40819983 No abstract available.
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
Meyer T, Finn RS, Borad M, Mahipal A, Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M, Evans TRJ, Wong KM, Tan BR, Mitry E, Sarker D, Feun L, El-Rayes B, Thistlethwaite F, Kaseb A, Alese O, Jin Z, Cirillo C, Bruix J, Roddie C, Noto P, Fayngerts S, Cristiani S, Sampson J, Bai J, Isabelle M, Broad R, Sun A, Norry E, Sangro B. Meyer T, et al. Among authors: houot r. J Hepatol. 2026 Jan;84(1):113-121. doi: 10.1016/j.jhep.2025.07.033. Epub 2025 Aug 12. J Hepatol. 2026. PMID: 40812667 Free article. Clinical Trial.
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.
Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet M, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, André M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas-Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens MC, Griolet S, Gaulard P, Delfau-Larue MH, de Leval L, Damaj GL. Tournilhac O, et al. Among authors: houot r. Blood Adv. 2025 Dec 23;9(24):6292-6304. doi: 10.1182/bloodadvances.2024015787. Blood Adv. 2025. PMID: 40758949 Free PMC article. Clinical Trial.
Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools.
Moinard S, Lebecque B, Lachaise T, Johnson-Ansah H, Doublet C, Roth-Guepin G, Rigal-Huguet F, Roy L, Parry A, Meunier M, Penot A, Legros L, Pante V, Escoffre-Barbe M, Rousselot P, Denis G, Monjanel H, Hamroun D, Khlaifia A, Besombes J, Pereira B, Bourgne C, Berger MG. Moinard S, et al. Among authors: escoffre barbe m. Leukemia. 2025 Oct;39(10):2375-2383. doi: 10.1038/s41375-025-02703-6. Epub 2025 Aug 1. Leukemia. 2025. PMID: 40750677 Free PMC article.
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.
Penichoux J, Decazes P, Rossi C, Sesques P, Haioun C, Durot E, Gower N, Willaume A, Oberic L, Paillassa J, Antier C, Renaud L, Tournilhac O, Thieblemont C, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Houot R, Chauchet A, Becker S, Tonnelet D, Tilly H, Jardin F, Lévêque E, Camus V. Penichoux J, et al. Among authors: houot r. Hematol Oncol. 2025 Jul;43(4):e70117. doi: 10.1002/hon.70117. Hematol Oncol. 2025. PMID: 40646709 Free PMC article.
Intermediate-Dose Cytarabine as Postinduction AML Therapy.
Hunault M, Pautas C, Bertoli S, Dumas PY, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carré M, Peterlin P, Gallego-Hernanz MP, Lemasle E, Guièze R, Simand C, Turlure P, Huynh A, Leguay T, Devillier R, Quoc SN, Duployez N, Luquet I, Penther D, Celli-Lebras K, Mineur A, Raus N, Gardin C, Socié G, Cahn JY, Ifrah N, Vey N, de Latour RP, Delabesse E, Preudhomme C, Hamel JF, Pigneux A, Récher C, Dombret H. Hunault M, et al. Among authors: marchand t. NEJM Evid. 2025 Jul;4(7):EVIDoa2400326. doi: 10.1056/EVIDoa2400326. Epub 2025 Jun 24. NEJM Evid. 2025. PMID: 40552969 Clinical Trial.
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.
Chalayer E, Frere C, Daguenet E, Lecompte T, Tardy B, Bounouara I, Sapet M, Bobin A, Harel S, Decaux O, Belhadj K, Touzeau C, Macro M, Mohty M, Moreau P, Corre J, Avet-Loiseau H, Karlin L, Facon T, Perrot A, Hulin C, Manier S, Frenzel L, Leleu X. Chalayer E, et al. Among authors: decaux o. J Thromb Haemost. 2025 Oct;23(10):3220-3230. doi: 10.1016/j.jtha.2025.06.012. Epub 2025 Jun 14. J Thromb Haemost. 2025. PMID: 40523501 Clinical Trial.
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study.
Talbot A, Hulin C, Perrot A, Macro M, Belhadj Merzoug K, Mohty M, Bobin A, Karlin L, Manier S, Vincent L, Yamani AE, Abarah W, Kaphan R, Chalopin T, Ré D, de Labarthe A, Fitoussi O, Lounis C, Garlantezec R, Decaux O; EMMY and the IFM group. Talbot A, et al. Among authors: decaux o. Clin Lymphoma Myeloma Leuk. 2025 Dec;25(12):863-872. doi: 10.1016/j.clml.2025.05.015. Epub 2025 May 21. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40518372 Free article.
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, Rouanet J, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators, Groupe Français d’Etude des Lymphomes Cutanés and Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Among authors: bernard m, houot r, mear jb. J Clin Oncol. 2025 Aug;43(22):2461-2466. doi: 10.1200/JCO-25-00183. Epub 2025 Jun 13. J Clin Oncol. 2025. PMID: 40513043 Free article.
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Mohty M, Leleu X, Manier S, Mariette C, Chaleteix C, Braun T, De Prijck B, Avet-Loiseau H, Mary JY, Corre J, Moreau P, Touzeau C; MIDAS Study Group. Perrot A, et al. Among authors: escoffre barbe m. N Engl J Med. 2025 Jul 31;393(5):425-437. doi: 10.1056/NEJMoa2505133. Epub 2025 Jun 3. N Engl J Med. 2025. PMID: 40459097 Clinical Trial.
CARs in pole position: ready for the race?
Manson G, Houot R. Manson G, et al. Among authors: houot r. Blood. 2025 May 15;145(20):2235-2236. doi: 10.1182/blood.2025028354. Blood. 2025. PMID: 40372741 No abstract available.
Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).
Chalandon Y, Devillier R, Boumendil A, Nguyen S, Bulabois CE, Ceballos P, Brissot E, Rubio MT, Labussière-Wallet H, Maertens J, Chevallier P, Maillard N, Poiré X, Castilla-Llorente C, Beguin Y, Cornillon J, Maury S, Marchand T, Daguindau E, Bay JO, Turlure P, Joris M, Menard AL, Bilger K, Guillerm G, François S, Bazarbachi A, Chantepie S, Lewalle P, Marçais A, Loschi M, Benakli M, Chauvet P, Forcade E, Huynh A, Robin M, Masouridi-Levrat S. Chalandon Y, et al. Among authors: marchand t. Am J Hematol. 2025 Jul;100(7):1173-1184. doi: 10.1002/ajh.27701. Epub 2025 May 6. Am J Hematol. 2025. PMID: 40326583 Free article.
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas.
Stephan P, Di Blasi R, Roulin L, Galtier J, Calvani J, Meignin V, Donzel M, Traverse-Glehen A, Poullot E, Parrens M, Dupont V, Marquet A, Le Gouill S, Houot R, Gros FX, Lemonnier F, Bachy E, Thieblemont C, Sesques P. Stephan P, et al. Among authors: houot r. Blood Adv. 2025 Sep 23;9(18):4693-4704. doi: 10.1182/bloodadvances.2025015834. Blood Adv. 2025. PMID: 40311067 Free PMC article.
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
Herbaux C, Bachy E, Bouabdallah R, Guidez S, Casasnovas O, Feugier P, Damaj G, Tilly H, Ysebaert L, Le Gouill S, Morineau N, Gyan E, Gressin R, Houot R, Cheminant M, Morschhauser F, Thieblemont C, Haioun C, Nicolas-Virelizier E, Fornecker LM, Daguindau N, Cartron G. Herbaux C, et al. Among authors: houot r. Br J Haematol. 2025 Jul;207(1):110-122. doi: 10.1111/bjh.20109. Epub 2025 Apr 26. Br J Haematol. 2025. PMID: 40285420 Free PMC article. Clinical Trial.
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Sarkozy C, Chartier L, Ribrag V, Gressin R, Geisler CH, Kluin-Nelemans HC, Thieblemont C, Morschhauser F, Lemonnier F, Safar V, Tessoulin B, Oberic L, Damaj G, Ghesquières H, Bouabdallah K, Casasnovas RO, Houot R, Klapper W, Burroni B, Pott C, Delfau-Larue MH, Macintyre E, Callanan M, Jerkeman M, Unterhalt M, Hoster E, Dreyling M, Le Gouill S, Hermine O, Cheminant M. Sarkozy C, et al. Among authors: houot r. Blood Cancer J. 2025 Apr 24;15(1):78. doi: 10.1038/s41408-025-01241-9. Blood Cancer J. 2025. PMID: 40274771 Free PMC article.
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.
Cartron G, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Casasnovas O, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, Drieu La Rochelle L, Feugier P, Marcais A, Griolet S, Tarte K, Laurent C, Sesques P. Cartron G, et al. Among authors: houot r. Nat Cancer. 2025 Jul;6(7):1173-1183. doi: 10.1038/s43018-025-00941-2. Epub 2025 Apr 3. Nat Cancer. 2025. PMID: 40181090 Free article. Clinical Trial.
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA.
Sarkozy C, Molina TJ, Dubois S, Portugues C, Bohers E, Ysebaert L, Houot R, Pica GM, Ruminy P, Herbaux C, Gastinne T, Thieblemont C, Haioun C, Guidez S, Bonnet C, Crochet G, Veresezan L, Choquet S, Bachy E, Jardin F, Morschhauser F, Ribrag V. Sarkozy C, et al. Among authors: houot r. EClinicalMedicine. 2025 Mar 18;82:103157. doi: 10.1016/j.eclinm.2025.103157. eCollection 2025 Apr. EClinicalMedicine. 2025. PMID: 40166656 Free PMC article.
It is time to consider the climate crisis in haematology.
Noel R, Charbonnier A, Schell B, Dony A, Toulemonde C, Eisinger F, Decaux O, Lotocka J, Julia E, Perthus A, Seguin M, Cabannes-Hamy A, Sujobert P, Marrauld L, Besson C. Noel R, et al. Among authors: decaux o. Clin Hematol Int. 2025 Mar 27;7(1):55-59. doi: 10.46989/001c.133524. eCollection 2025. Clin Hematol Int. 2025. PMID: 40161264 Free PMC article. No abstract available.
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines.
Renaud L, Donzel M, Decroocq J, Decazes P, Galtier J, Burroni B, Veresezan EL, Sesboüé C, Dartigues P, Chassagne-Clément C, Martin L, Mauduit C, Kaltenbach S, Penther D, Etancelin P, Sibon D, Bailly S, Martin V, Durot E, Kirova Y, Grenier A, Maerevoet M, Bernard W, Naveau L, Cabannes-Hamy A, Cottereau AS, Jacquet-Francillon N, Noel R, Reichert T, Sarkozy C, Bussot L, Bailly S, Amorim S, Krzisch D, Cornillon J, Legendre H, Chevillon F, Cavalieri D, Sesques P, Minard-Colin V, Haioun C, Morschhauser F, Houot R, Jardin F, Tilly H, Traverse-Glehen A, Camus V. Renaud L, et al. Among authors: houot r. Eur J Cancer. 2025 May 2;220:115369. doi: 10.1016/j.ejca.2025.115369. Epub 2025 Mar 22. Eur J Cancer. 2025. PMID: 40157284 Free article. Review.
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Shah BD, et al. Among authors: houot r. Leukemia. 2025 May;39(5):1058-1068. doi: 10.1038/s41375-025-02532-7. Epub 2025 Mar 19. Leukemia. 2025. PMID: 40108332 Free PMC article.
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020.
Vincent L, Decaux O, Perrot A, Royer B, Chalopin T, Bobin A, Macro M, Caillot D, Karlin L, Jacquet C, Sonntag C, Mohty M, Frenzel L, Jaccard A, Manier S, Sanhes L, Chaoui D, Moreau P, Garlantézec R, Texier N, Louni C, Maarouf Z, Loiseau HA, Hulin C, Merzoug KB. Vincent L, et al. Among authors: decaux o. Cancer Med. 2025 Mar;14(6):e70619. doi: 10.1002/cam4.70619. Cancer Med. 2025. PMID: 40087879 Free PMC article.
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.
Camus V, Molina T, Desmots F, Blanc-Durand P, Kanoun S, Moslemi A, Ruminy P, Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Houot R, Thieblemont C, Maisonneuve H, Claves F, Bouabdallah K, Haioun C, Damaj GL, Fornecker LM, Noel R, Feugier P, Sibon D, Cartron G, Bonnet C, Bernard W, Kraeber-Bodéré F, Bodet-Milin C, Jais JP, Brière J, Rossi C, Elsensohn MH, Chartier L, Itti E, Jardin F, Fest T. Camus V, et al. Among authors: houot r. Blood Adv. 2025 May 13;9(9):2232-2246. doi: 10.1182/bloodadvances.2024015577. Blood Adv. 2025. PMID: 40030008 Free PMC article. Clinical Trial.
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France.
Bigenwald C, Roos-Weil D, Pagès A, Hélias-Rodzewicz Z, Copie-Bergman C, Nashvi M, Khneisser P, Parrens M, Traverse-Glehen A, Ray-Coquard I, Ysebaert L, Marchand T, Razanamahery J, Charlotte F, Neel A, Damaj G, Dion J, Nazal-Traissac EM, Tardy S, Salmeron G, Monjanel H, Idbaih A, Héritier S, Haroche J, Donadieu J, Emile JF. Bigenwald C, et al. Among authors: marchand t. Blood Adv. 2025 May 27;9(10):2530-2541. doi: 10.1182/bloodadvances.2024015208. Blood Adv. 2025. PMID: 40009752 Free PMC article.
Remote Monitoring of CAR T-Cell Treated Patients by a Specialized Nurse to Detect and Manage Late Complications: Report of the CARAMA Program.
Colin F, Bellec A, Le Bars L, Granger M, Lucas L, Ricard T, de Guibert S, Manson G, Lhomme F, Marchand T, Méar JB, Escoffre M, Decaux O, Lamy T, Houot R, Moignet A. Colin F, et al. Among authors: lamy t, houot r, mear jb, manson g, de guibert s, decaux o, escoffre m, moignet a, lhomme f, marchand t. Hematol Oncol. 2025 Mar;43(2):e70052. doi: 10.1002/hon.70052. Hematol Oncol. 2025. PMID: 39983083 No abstract available.
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry.
Galtier J, Mesguich C, Sesques P, Dupont V, Bachy E, Di Blasi R, Thieblemont C, Gastinne T, Cartron G, Brisou G, Gros FX, Decroocq J, Morschhauser F, Rubio MT, Drieu La Rochelle L, Le Bras F, Carras S, Chauchet A, Bay JO, Joris M, Loschi M, Tanguy-Schmidt A, Marquet A, Camus V, Le Gouill S, Houot R, Bouabdallah K. Galtier J, et al. Among authors: houot r. Hemasphere. 2025 Feb 18;9(2):e70091. doi: 10.1002/hem3.70091. eCollection 2025 Feb. Hemasphere. 2025. PMID: 39968186 Free PMC article.
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02).
Bertoli S, Bérard E, Peterlin P, Guieze R, Desbrosses Y, Hicheri Y, Benbrahim O, Carre M, Orvain C, Banos A, Bernard M, Gyan E, Saad A, Chebrek S, Guepin GR, Dorvaux V, Sanhes L, Gallego-Hernanz MP, Exbrayat C, Vincent L, Himberlin C, Simand C, Vey N, Fenoll C, Mineur A, Huynh A, Vergez F, Luquet I, Largeaud L, Delabesse E, Pigneux A, Récher C. Bertoli S, et al. Among authors: bernard m. Haematologica. 2025 Oct 1;110(10):2475-2480. doi: 10.3324/haematol.2024.286807. Epub 2025 Feb 6. Haematologica. 2025. PMID: 39911128 Free PMC article. No abstract available.
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.
Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini-Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hebraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MC, Bigot N, Avet-Loiseau H, Corre J, Moreau P. Perrot A, et al. Among authors: escoffre barbe m. Blood. 2025 Jul 3;146(1):52-61. doi: 10.1182/blood.2024026230. Blood. 2025. PMID: 39841461 Clinical Trial.
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA.
Marouf A, Chaubard S, Liévin R, Michot JM, Molinari N, Rossignol J, Cavalieri D, Golfier C, Allangba O, Philippe L, Tessoulin B, Chauchet A, Deau B, Oberic L, Vargaftig J, Moignet A, Clavert A, Dulery R, Brisou G, Tardy S, Fataccioli V, Houot R, Casasnovas RO, Thieblemont C, Ghesquières H, Carras S, Le Gouill S, Cartron G, Ribrag V, Cheminant M, Marçais A, Suarez F, Marabelle A, Tournilhac O, Damaj G, Gaulard P, De Leval L, Lemonnier F, Bachy E, Chevret S, Hermine O, Couronné L, Jaccard A. Marouf A, et al. Among authors: houot r, moignet a. Hemasphere. 2025 Jan 20;9(1):e70081. doi: 10.1002/hem3.70081. eCollection 2025 Jan. Hemasphere. 2025. PMID: 39840381 Free PMC article. No abstract available.
Postoperative stage 0 Hodgkin lymphoma. Is surgery alone a curative option?
Couturier A, Judet A, Touati M, Nivet T, Daufresne P, Claves F, Durot E, Duléry R, Houot R, Manson G. Couturier A, et al. Among authors: houot r, manson g. Hemasphere. 2025 Jan 15;9(1):e70076. doi: 10.1002/hem3.70076. eCollection 2025 Jan. Hemasphere. 2025. PMID: 39816530 Free PMC article. No abstract available.
T cell malignancies after CAR T cell therapy in the DESCAR-T registry.
Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, Todesco È, Arnulf B, Boissel N, Baruchel A, Bay JO, Le Gouill S, Houot R. Dulery R, et al. Among authors: houot r. Nat Med. 2025 Apr;31(4):1130-1133. doi: 10.1038/s41591-024-03458-w. Epub 2025 Jan 8. Nat Med. 2025. PMID: 39779930 Free article.
Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
Touzeau C, Leleu X, Tiab M, Macro M, Perrot A, Gay J, Chateleix C, Moreau S, Karlin L, Jacquet C, Manier S, Hulin C, Decaux O, Richez V, Chalopin T, Mohty M, Orsini-Piocelle F, Caillot D, Sonntag C, Vignon M, Bobin A, Avet-Loiseau H, Jobert A, Planche L, Corre J, Moreau P. Touzeau C, et al. Among authors: decaux o. Br J Haematol. 2025 May;206(5):1366-1372. doi: 10.1111/bjh.19978. Epub 2025 Jan 5. Br J Haematol. 2025. PMID: 39757748 Clinical Trial.
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, García-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W. Shadman M, et al. Among authors: de guibert s. J Clin Oncol. 2025 Mar;43(7):780-787. doi: 10.1200/JCO-24-02265. Epub 2024 Dec 8. J Clin Oncol. 2025. PMID: 39647999 Free PMC article. Clinical Trial.
High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.
Calvo J, Naguibneva I, Kypraios A, Gilain F, Uzan B, Gaillard B, Bellenger L, Renou L, Antoniewski C, Lapillonne H, Petit A, Ballerini P, Mancini SJ, Marchand T, Peyron JF, Pflumio F. Calvo J, et al. Among authors: marchand t. Leukemia. 2025 Feb;39(2):323-336. doi: 10.1038/s41375-024-02473-7. Epub 2024 Nov 24. Leukemia. 2025. PMID: 39580584 Free PMC article.
Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with highrisk cytogenetics: the IFM 2014-01 study.
Bobin A, Manier S, De Keizer J, Srimani JK, Hulin C, Karlin L, Caillot D, Lafon I, Mariette C, Araujo C, Arnulf B, Bareau B, Belhadj K, Benboubker L, Braun T, Calmettes C, Decaux O, Dib M, Demarquette H, Jacquet C, Sonntag C, Godet S, Jaccard A, Lenain P, Macro M, Richez-Olivier V, Tiab M, Vincent L, Zerazhi H, Pétillon MO, Rollet S, Gardeney H, Durand G, Levy A, Touzeau C, Perrot A, Moreau P, Facon T, Corre J, Ragot S, Avet-Loiseau H, Leleu X. Bobin A, et al. Among authors: decaux o. Haematologica. 2025 Mar 1;110(3):758-763. doi: 10.3324/haematol.2024.285916. Haematologica. 2025. PMID: 39540213 Free PMC article. No abstract available.
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.
Di Staso R, Casadei B, Locke FL, Jain M, Voorhees TJ, Kittai AS, Bastos-Oreiro M, Gutiérrez A, Martin Garcia-Sancho A, Terol MJ, Mead M, Maranzano MJ, Iacoboni G, Barba P, Kwon M, Bailen R, Reguera-Ortega JL, Mian A, Hill B, Bachy E, Morschhauser F, Houot R, Thieblemont C, Le Gouill S, Masetti R, Gori D, Broccoli A, Zinzani PL, Argnani L. Di Staso R, et al. Among authors: houot r. Blood Cancer J. 2024 Nov 7;14(1):197. doi: 10.1038/s41408-024-01183-8. Blood Cancer J. 2024. PMID: 39511146 Free PMC article. No abstract available.
Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.
Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, Alcantara M, Molina L, Ceraulo A, Poirée M, Galtier J, Diop N, Delette C, Segot A, Dubois S, Waultier A, Bernard S, Noël R, Guidez S, Kohn M, Bailly S, Moatti H, Touati M, Renaud L, Kanoun S, Cottereau AS, Kirova Y, Peignaux K, Dourthe ME, Simonin M, Leblanc T, Quéro L, Krzisch D, Duléry R, Grenier A, Gastinne T, Casasnovas O, Gallamini A, André M, Morschhauser F, Deau B, Fornecker LM, Ghesquières H. Rossi C, et al. Among authors: manson g. Eur J Cancer. 2024 Dec;213:115073. doi: 10.1016/j.ejca.2024.115073. Epub 2024 Oct 22. Eur J Cancer. 2024. PMID: 39509848 Free article. Review.
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
Alcantara M, Chevrier M, Jardin F, Schmitt A, Houillier C, Oberic L, Chinot O, Morschhauser F, Peyrade F, Houot R, Hoang-Xuan K, Ghesquieres H, Soussain C. Alcantara M, et al. Among authors: houot r. J Hematol Oncol. 2024 Oct 19;17(1):98. doi: 10.1186/s13045-024-01620-y. J Hematol Oncol. 2024. PMID: 39427203 Free PMC article. No abstract available.
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, Hicheri Y, Wartiovaara-Kautto U, Raffoux E, Cluzeau T, Balsat M, Roth-Guepin G, Tavernier E, Lepretre S, Bilger K, Bergugnat H, Berceanu A, Alexis M, Doubek M, Brissot E, Hunault-Berger M, Lebon D, Turlure P, Chantepie S, Belhabri A, Wickenhauser S, Bastie JN, Cacheux V, Himberlin C, Banos A, Gardin C, Bonnet S, Plantier I, Pica GM, Escoffre-Barbe M, Boissel N, Dombret H, Clappier E, Rousselot P; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL). Chevallier P, et al. Among authors: escoffre barbe m. J Clin Oncol. 2024 Dec 20;42(36):4327-4341. doi: 10.1200/JCO.24.00490. Epub 2024 Oct 17. J Clin Oncol. 2024. PMID: 39418626 Clinical Trial.
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
Alcantara M, Chevrier M, Jardin F, Schmitt A, Houillier C, Oberic L, Chinot O, Morschhauser F, Peyrade F, Houot R, Hoang-Xuan K, Ghesquieres H, Soussain C. Alcantara M, et al. Among authors: houot r. J Hematol Oncol. 2024 Sep 19;17(1):86. doi: 10.1186/s13045-024-01606-w. J Hematol Oncol. 2024. PMID: 39300447 Free PMC article. Clinical Trial.
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).
Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, Turlure P, Reimer P, Wagner-Drouet E, Sanhes L, Houot R, Roussel M, Kroschinsky F, Dreger P, Viardot A, de Leval L, Rosenwald A, Gaulard P, Wulf G, Villate A, Latiere C, Elmaagacli A, Glass B, Poeschel V, Damaj G, Sibon D, Durot E, Bilger K, Banos A, Haenel M, Dreyling M, Keller U, Tiab M, Drenou B, Cornillon J, Nguyen S, Robin M, Nickelsen M, Trümper L, Lenz G, Ziepert M, Schmitz N; French Lymphoma Study Association (LYSA), the Société Francophone de greffe de moelle et Thérapie Cellulaire (SFGM-TC), and the German Lymphoma Alliance (GLA). Tournilhac O, et al. Among authors: houot r. J Clin Oncol. 2024 Nov 10;42(32):3788-3794. doi: 10.1200/JCO.24.00554. Epub 2024 Sep 13. J Clin Oncol. 2024. PMID: 39270145 Clinical Trial.
[Nurturing and growing a community of department heads: Act 2 in haematology].
Houot R, Calmettes C, Park S, Pascal L, Peffault de Latour R, Pigneux A, Quinquenel A, Raffoux E, Thieblemont C, Touati M, Trebouet A, Vaida I, Wémeau M, Bastie JN, Bay JO, Cluzeau T, Cornillon J, Damaj G, Deconinck E, Feugier P, Fornecker LM, Gay J, Hermine O, Hospital MA, Hunault M, Jaccard A, Jardin F, Le Calloch R, Legros L, Leleu X, Lemonnier F, Malfuson JV, Morel P, Ochmann M, Orsini-Piocelle F, Gyan E. Houot R, et al. Bull Cancer. 2024 Oct;111(10):980-986. doi: 10.1016/j.bulcan.2024.06.014. Epub 2024 Sep 11. Bull Cancer. 2024. PMID: 39266427 Free article. French.
[Real-life evaluation of the care pathway of patients eligible for axicabtagene ciloleucel treatment: Analysis of a multicenter retrospective cohort (IMPA-CT study)].
Cartron G, Thieblemont C, Borget I, Rioufol C, Berthet M, Portal C, Baujat C, Alaoui E, Baffert S, Lacroix D, Bories P, Yakoub-Agha I, Houot R. Cartron G, et al. Among authors: houot r. Bull Cancer. 2024 Nov;111(11):1020-1029. doi: 10.1016/j.bulcan.2024.07.010. Epub 2024 Sep 11. Bull Cancer. 2024. PMID: 39266425 French.
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma.
Maurer K, Grabski IN, Houot R, Gohil SH, Miura S, Redd R, Lyu H, Lu W, Arihara Y, Budka J, McDonough M, Ansuinelli M, Reynolds C, Jacene H, Li S, Livak KJ, Ritz J, Miles B, Mattie M, Neuberg DS, Irizarry RA, Armand P, Wu CJ, Jacobson C. Maurer K, et al. Among authors: houot r. Blood. 2024 Dec 12;144(24):2490-2502. doi: 10.1182/blood.2024024381. Blood. 2024. PMID: 39241199 Free PMC article.
Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.
Rabian F, Beauvais D, Marchand T, Fürst S, Huynh A, Brissot E, Maury S, Gabellier L, Chevallier P, Loschi M, Nguyen S, Balsat M, Lafon I, Fayard A, Camus V, Simand C, Moya N, Castilla-Llorente C, Joris M, Berceanu A, Thiebaut-Bertrand A, Lhéritier V, Gehlkopf E, Roth-Guépin G, Leguay T, Boissel N. Rabian F, et al. Among authors: marchand t. Blood Adv. 2024 Nov 12;8(21):5493-5496. doi: 10.1182/bloodadvances.2024013962. Blood Adv. 2024. PMID: 39207868 Free PMC article. No abstract available.
Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies.
Boulland ML, Aliouat A, Jalaber E, Desmares A, Toujani S, Luque Paz D, Wiber M, Voirin E, Lachot S, Basinko A, Lambert WC, Carras S, Cousin E, Marchand T, de Tayrac M, Fest T, Houot R, Pastoret C. Boulland ML, et al. Among authors: houot r, marchand t. J Mol Diagn. 2024 Nov;26(11):1007-1017. doi: 10.1016/j.jmoldx.2024.07.004. Epub 2024 Aug 31. J Mol Diagn. 2024. PMID: 39182671 Free article.
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, Decroocq J, Krzisch D, Oberic L, Lemonnier F, Bouabdallah K, Campidelli A, Tounes L, Abraham J, Herbaux C, Morschhauser F, Damaj GL, Guidez S, Carras S, Fornecker LM, Choquet S, Hermine O, Paillassa J, Chauchet A, Casasnovas O, Drieu La Rochelle L, Castilla-Llorente C, Joris M, Dupont V, Marquet A, Le Gouill S, Jardin F. Camus V, et al. Among authors: houot r. Blood Adv. 2024 Oct 22;8(20):5371-5381. doi: 10.1182/bloodadvances.2024013726. Blood Adv. 2024. PMID: 39163620 Free PMC article.
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial.
Guièze R, Ysebaert L, Roos-Weil D, Fornecker LM, Ferrant E, Molina L, Aurran T, Clavert A, de Guibert S, Michallet AS, Saad A, Drénou B, Quittet P, Hivert B, Laribi K, Gay J, Quinquenel A, Broseus J, Rouille V, Schwartz D, Magnin B, Lazarian G, Véronèse L, de Antonio M, Laurent C, Tournilhac O, Pereira B, Feugier P. Guièze R, et al. Among authors: de guibert s. Nat Commun. 2024 Aug 9;15(1):6822. doi: 10.1038/s41467-024-51264-2. Nat Commun. 2024. PMID: 39122717 Free PMC article. Clinical Trial.
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.
Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E. Sesques P, et al. Among authors: houot r. J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w. J Hematol Oncol. 2024. PMID: 39107847 Free PMC article.
Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel.
Couturier A, Escoffre M, Leh F, Villoteau AS, Palard X, Le Jeune F, Decaux O, Lamy T, Houot R. Couturier A, et al. Among authors: lamy t, houot r, decaux o, escoffre m. Hemasphere. 2024 Jul 25;8(7):e131. doi: 10.1002/hem3.131. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39055647 Free PMC article. No abstract available.
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge.
Decaux O, Garlantézec R, Belhadj-Merzoug K, Macro M, Frenzel L, Perrot A, Moreau P, Royer B, Caillot D, Leleu X, Mohty M, Karlin L, Feugier P, Rigaudeau S, Fontan J, Sonntag C, Vincent L, Chalopin T, Avet Loiseau H, Maarouf Z, Chanaz L, Texier N, Hulin C. Decaux O, et al. Clin Hematol Int. 2024 Jul 23;6(3):22-27. doi: 10.46989/001c.121371. eCollection 2024. Clin Hematol Int. 2024. PMID: 39050939 Free PMC article.
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma.
van Meerten T, Kuruvilla J, Song KW, Thieblemont C, Minnema MC, Forcade E, De Guibert S, Kersten MJ, Mutsaers PG, Wermke M, Zheng Y, Xue A, Winters JN, Nater J, Shen RR, Spooner C, Neumann F, Kim JJ, Topp MS. van Meerten T, et al. Among authors: de guibert s. Am J Cancer Res. 2024 Jun 15;14(6):2905-2920. doi: 10.62347/LLXR8002. eCollection 2024. Am J Cancer Res. 2024. PMID: 39005691 Free PMC article.
700 results